הודעות, עדכונים וחדשות
המייל האדום של מדנט
פספסנו ידיעה חשובה? דווחו אתם לנו - חדשות, מחקרים, סקירות וידיעות מעניינות. עזרו לנו לספק את מירב התוכן האיכותי עבורכם
לחצו עכשיו לשליחת ידיעה
Risks of Delaying Bladder Cancer Diagnosis- Surveillance and Surgery During COVID-19
The rapid spread of Coronavirus Disease 2019 (COVID-19), caused by the betacoronavirus SARS-CoV-2, throughout the world has had dramatic effects on healthcare systems with impacts far beyond the patients actually infected with COVID-19
Adjuvant Chemotherapy Shows Strong Benefit in Upper Tract Urothelial Carcinoma
Adjuvant platinum-based chemotherapy reduced the risk of disease recurrence or death by 55% in patients with upper tract urothelial carcinoma (UTUC), according to findings from the phase III POUT trial that have now been published in The Lancet
Savolitinib Shows Promising Efficacy Data in Papillary Renal Cell Carcinoma
Savolitinib showed encouraging efficacy data and an improved safety profile compared with sunitinib (Sutent) as a treatment for patients with MET-driven papillary renal cell carcinoma (RCC), according to results that were presented during the 2020 ASCO Virtual Scientific Program
Tivozanib Showcases Superiority in Relapsed/Refractory RCC
Tivozanib (Fotivda) demonstrated a significant improvement in progression-free survival (PFS) compared with sorafenib (Nexavar), with similar overall survival (OS), in patients with highly relapsed.refractory metastatic renal cell carcinoma (RCC), according to results of the phase 3 TIVO-3 trial presented at the 2020 ASCO Virtual Scientific Program
Adjuvant Atezolizumab Misses DFS Endpoint in Muscle-Invasive Bladder Cancer
Adjuvant treatment with atezolizumab (Tecentriq) did not significantly improve disease-free survival (DFS) compared with observation in patients with muscle-invasive bladder cancer, missing the primary endpoint of the phase III IMvigor010 trial
FDA Approves Olaparib for HRR-Mutant mCRPC
The FDA has approved olaparib (Lynparza) for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide (Xtandi) or abiraterone acetate
FDA Approves Rucaparib for BRCA+ mCRPC
The FDA has granted rucaparib (Rubraca) an accelerated approval for the treatment of adult patients with BRCA mutation (germline and/or somatic)–associated metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor–directed therapy and a taxane-based chemotherapy
Meta-Analysis Finds Adding ADT to EBRT Extends Survival in Localized Prostate Cancer
External beam radiotherapy (EBRT) plus androgen deprivation therapy (ADT) showed superior overall survival (OS) compared with EBRT plus a brachytherapy boost (BT) in men with intermediate- and high-risk prostate cancer
Phase II TheraP Trial Shows Promise for LuPSMA in mCRPC
Results from the TheraP trial, presented at the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program, found that in men with metastatic castration resistant prostate cancer (mCRPC) who progressed after treatment with docetaxel, 177Lu-PSMA-617 (LuPSMA) was more active than cabazitaxel
PD-L1 Expression on Tumour-Infiltrating Immune Cells Has No Prognostic Value in Renal Cell Carcinoma
Programmed death ligand 1 (PD-L1) status on tumour-infiltrating immune cells was not an independent prognostic factor for patients with recurrent or metastatic renal cell carcinoma, according to a study presented at the 2020 American Urological Association (AUA) Virtual Meeting
MR-Guided Focused Ultrasound Therapy Is Effective for Grade Group 2, 3 Prostate Cancer
Magnetic resonance-guided focused ultrasound (MRgFUS) focal therapy using real-time MR thermometry is effective for grade group 2 and 3 prostate cancer, according to a study presented at the 2020 American Urological Association (AUA) Virtual Meeting
Avelumab Extends Survival as Frontline Maintenance in Urothelial Carcinoma
Adding avelumab (Bavencio) to best supportive care (BSC) improved the median overall survival (OS) by over 7 months in patients with locally advanced or metastatic urothelial carcinoma, according to findings from the phase 3 JAVELIN Bladder 100 study presented during the 2020 ASCO Virtual Scientific Program
